USP47 inhibition blocked the function of mutated EZH2 through ubiquitination and EZH2 degradation, increasing the sensitivity of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) cells to EZH2 inhibitors, such as the recently FDA-approved EPZ-6438, in vitro and in vivo11. Here, EZH2 is linked to acute myeloid leukemia.